EP
RCUS icon

Essential Partners’s Arcus Biosciences RCUS Stock Holding History

Essential Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$771 Hold
25
– – ﹤0.01% 2348
2026
Q1 		$540 Hold
25
– – ﹤0.01% 2413
2025
Q4 		$596 Hold
25
– – ﹤0.01% 2186
2025
Q3 		$340 Hold
25
– – ﹤0.01% 2288
2025
Q2 		$204 Buy
+25
New +$214 ﹤0.01% 1938

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Essential Partners's RCUS Position: Q2 2026 in Review

Essential Partners held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 25 shares worth $771. The position accounts for ﹤0.01% of the portfolio, ranked #2348.

Essential Partners first reported a position in RCUS in Q2 2025 and has held it in 5 quarters since. 230 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Essential Partners held 25 shares of Arcus Biosciences worth $771 as of Q2 2026.
  • Essential Partners left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2348 holding.
  • Essential Partners first reported a position in Arcus Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 230 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.